S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:ARAY

Accuray - ARAY Stock Forecast, Price & News

$2.68
+0.04 (+1.52%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.58
$2.68
50-Day Range
$1.76
$2.68
52-Week Range
$1.70
$5.93
Volume
635,973 shs
Average Volume
928,011 shs
Market Capitalization
$248.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Accuray MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
173.6% Upside
$7.33 Price Target
Short Interest
Bearish
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.47mentions of Accuray in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
800.00%
From $0.04 to $0.36 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

283rd out of 1,117 stocks

Surgical & Medical Instruments Industry

24th out of 113 stocks

ARAY stock logo

About Accuray (NASDAQ:ARAY) Stock

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Accuray Price Performance

ARAY traded up $0.03 on Friday, hitting $2.67. 21,203 shares of the company's stock were exchanged, compared to its average volume of 532,252. Accuray has a fifty-two week low of $1.70 and a fifty-two week high of $5.93. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 3.36. The firm has a 50-day moving average price of $2.07 and a 200-day moving average price of $2.76. The stock has a market cap of $247.78 million, a price-to-earnings ratio of -44.50 and a beta of 1.82.

Accuray (NASDAQ:ARAY - Get Rating) last announced its earnings results on Wednesday, August 10th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. Accuray had a negative net margin of 1.24% and a negative return on equity of 10.81%. During the same quarter in the previous year, the firm posted ($0.01) EPS. As a group, equities analysts anticipate that Accuray will post 0.04 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARAY has been the subject of several recent research reports. TheStreet lowered shares of Accuray from a "c-" rating to a "d" rating in a report on Thursday, April 28th. BTIG Research cut their target price on shares of Accuray from $9.00 to $7.00 and set a "buy" rating for the company in a report on Friday, June 24th. StockNews.com raised shares of Accuray from a "hold" rating to a "buy" rating in a report on Monday. Finally, B. Riley initiated coverage on shares of Accuray in a report on Thursday, June 23rd. They set a "buy" rating and a $7.50 target price for the company. Four investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $7.33.

Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

Accuray Incorporated Q4 Loss Narrows
Accuray (NASDAQ:ARAY) Raised to Buy at StockNews.com
See More Headlines
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Company Calendar

Last Earnings
8/10/2022
Today
8/12/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
995
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+173.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-6,310,000.00
Pretax Margin
-2.62%

Debt

Sales & Book Value

Annual Sales
$429.91 million
Cash Flow
$0.15 per share
Book Value
$0.74 per share

Miscellaneous

Free Float
89,090,000
Market Cap
$248.71 million
Optionable
Optionable
Beta
1.82

Social Links















ARAY Stock - Frequently Asked Questions

Should I buy or sell Accuray stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings
or view top-rated stocks.

What is Accuray's stock price forecast for 2022?

3 brokers have issued twelve-month price objectives for Accuray's stock. Their ARAY share price forecasts range from $7.00 to $7.50. On average, they anticipate the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price.
View analysts price targets for ARAY
or view top-rated stocks among Wall Street analysts.

How have ARAY shares performed in 2022?

Accuray's stock was trading at $4.77 at the beginning of 2022. Since then, ARAY shares have decreased by 43.8% and is now trading at $2.68.
View the best growth stocks for 2022 here
.

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ARAY earnings forecast
.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings results on Wednesday, August, 10th. The medical equipment provider reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Accuray had a negative net margin of 1.24% and a negative trailing twelve-month return on equity of 10.81%. During the same period last year, the business earned ($0.01) earnings per share.

What guidance has Accuray issued on next quarter's earnings?

Accuray issued an update on its FY 2023 earnings guidance on Friday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $447.00 million-$455.00 million, compared to the consensus revenue estimate of $425.20 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Royce & Associates LP (2.85%), Assenagon Asset Management S.A. (1.78%), Lapides Asset Management LLC (0.85%), Primecap Management Co. CA (0.46%), North Star Investment Management Corp. (0.34%) and Russell Investments Group Ltd. (0.25%). Insiders that own company stock include Andrew J Kirkpatrick, Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends
.

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.68.

How much money does Accuray make?

Accuray (NASDAQ:ARAY) has a market capitalization of $248.71 million and generates $429.91 million in revenue each year. The medical equipment provider earns $-6,310,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Accuray have?

The company employs 995 workers across the globe.

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More

When was Accuray founded?

Accuray was founded in 1990.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The official website for the company is www.accuray.com. The medical equipment provider can be reached via phone at (408) 716-4600, via email at mpolyviou@evcgroup.com, or via fax at 408-716-4601.

This page (NASDAQ:ARAY) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.